MET and mantle cell lymphoma: More clinical trials using a combination of c‐Met inhibitors with PIs may be designed to determine whether the administration of this agent to patients clinically progressing on a carfilzomib‐based regimen can reverse this phenotype and restore PI drug sensitivity in MCL.